Share Price Movements and Clinical Studies - Research Report on Celldex Therapeutics, Envision, MannKind, Covance, and Auxilium

NEW YORK, December 19, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Celldex Therapeutics, Inc. (NYSE: CLDX), Envision Healthcare Holdings, Inc. (NYSE: EVHC), MannKind Corp. (NASDAQ: MNKD), Covance Inc. (NYSE: CVD), and Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Celldex Therapeutics, Inc. Research Report

On December 16, 2013, Celldex Therapeutics, Inc.'s (Celldex Therapeutics) stock increased 5.28%, ending the day at $23.71. Over the previous three trading sessions, shares of Celldex Therapeutics increased 7.53%, compared to the Nasdaq Composite which increased 0.64% during the same period. The Full Research Report on Celldex Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/b443_CLDX

--

Envision Healthcare Holdings, Inc. Research Report

On December 16, 2013, Envision Healthcare Holdings, Inc.'s (Envision) stock increased 2.68%, ending the day at $33.31. Over the previous three trading sessions, shares of Envision increased 6.56%, compared to the Dow Jones Industrial Average which advanced 0.26% during the same period. The Full Research Report on Envision Healthcare Holdings, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/4b31_EVHC

--

MannKind Corp. Research Report

On December 16, 2013, MannKind Corp.'s (MannKind) stock declined 0.40%, ending the day at $4.96. Over the previous three trading sessions, shares of MannKind increased 3.12%, compared to the Nasdaq Composite which went up 0.64% during the same period. The Full Research Report on MannKind Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/044e_MNKD

--

Covance Inc. Research Report

On December 16, 2013, Covance Inc.'s (Covance) stock declined 0.73%, ending the day at $85.41. Over the previous three trading sessions, shares of Covance increased 0.15%, compared to the Dow Jones Industrial Average, which gained 0.26% during the same period. The Full Research Report on Covance Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/5691_CVD

--

Auxilium Pharmaceuticals Inc. Research Report

On December 13, 2013, Auxilium Pharmaceuticals Inc. (Auxilium) announced that the first patient was dosed in its Phase 2b study of collagenase clostridium histolyticum (CCH) for the treatment of adult patients with adhesive capsulitis, commonly known as Frozen Shoulder syndrome (FSS). Adrian Adams, CEO and President of Auxilium, commented, "The initiation of our Phase 2b Frozen Shoulder syndrome study represents another development milestone for Auxilium as we further evolve our pipeline and advance a fourth potential indication for CCH. We believe that our continued measured investments in research and development, together with the upcoming product launches of XIAFLEX in Peyronie's disease and STENDRA™ in erectile dysfunction, position the Company well for growth and shareholder value creation." The Company informed that Phase 2b study is a double-blind, placebo-controlled study of the effectiveness and safety of CCH for the treatment of Stage 2 (frozen stage) unilateral idiopathic FSS. Auxilium stated that the study will enroll about 300 adult men and women at approximately 35 sites in the U.S. and Australia wherein subjects will be randomized 3:1 to receive CCH or placebo and will be given upto three ultrasound-guided injections of study drug. The Company stated that each injection will be give after at least 21 days, and all subjects will do home shoulder exercises following the first injection. Auxilium added that Phase 2b study's primary endpoint is the change (degrees) from baseline to the Day 95 follow-up visit in active forward flexion in the affected shoulder compared to placebo. The Full Research Report on Auxilium Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/86a4_AUXL

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts' Corner